Top 10 Drug List for 2026
Key Takeaways
- Clearway Health helps hospitals prepare for emerging specialty medications. The 2026 Top 10 Drug List Report identifies newly approved and high-growth specialty therapies so health systems can evaluate formulary additions, plan patient access strategies, and stay ahead of evolving treatment trends.
- New specialty drugs are transforming care across multiple disease areas. The report highlights innovative therapies in oncology, dermatology, cardiology, weight management, HIV prevention (PrEP) and pulmonary fibrosis, reflecting the rapid pace of advancement in specialty pharmacy.
- Early access to FDA-approved therapies improves patient outcomes. By helping hospitals quickly adopt new medications, specialty pharmacy teams can expand treatment access, enhance care quality and connect patients with safer, more effective, and more targeted therapies.
Clearway Health’s specialty pharmacy teams are experts in staying current on medications that are recently approved or newly available in the market. We recently released our 2026 Top 10 2026 Drug List Report of growth-driver specialty medications that we are helping our hospitals and health systems track, stay educated on and actively seek formulary additions to make these medications available to patients as soon as possible.
These drugs treat conditions such as oncology, dermatology and cardiology as well as continuously evolving therapies for weight management, pre-exposure prophylaxis (PrEP) and pulmonary fibrosis. Expanding access to vital new medications approved by the U.S. Food and Drug Administration (FDA) has a waterfall effect of expanding patient access to the latest and most innovative medications, improving care and health outcomes by improving the safety, efficacy and targeting of treatments.
Click here to view a full image of this infographic.